Expert Interviews
New Trends in IPF
- Launched: November 30, 2015
Luca Richeldi, MD, PhD
University of Southampton
Dr. Richeldi addresses the following questions:
- What developments in treatment of IPF were presented at the PFF annual meeting?
- What is the role of patient registries in IPF?
- Have there been any clinical studies of pirfenidone combined with nintedanib?
Related Videos
Biomarkers for IPF
Naftali Kaminski, MD
Yale School of Medicine
Dr. Kaminski addresses the following questions:
- Which biomarkers have been investigated for IPF?
- Are there biomarkers that help diagnosis of IPF?
- Are there biomarkers for prognosis or monitoring of IPF?
- Can biomarkers influence disease management choices?
- Is there a role for genetic testing in IPF?
Discovering New Drugs for IPF
Andrew M. Tager, MD
Harvard Medical School
Dr. Tager addresses the following questions:
- How do nintedanib and pirfenidone work?
- Which targets are being investigated in the search for new drugs?
- Which drug candidates might emerge in the near future?
- Are there drugs for other indications that might be useful for IPF?
